Stockscreener 앱 받기
1.00
7.41%
-0.08
시장 영업 전:
1.05
0.05
+5.00%
전일 마감가:
$1.08
열려 있는:
$1.06
하루 거래량:
168.57K
Relative Volume:
1.27
시가총액:
$4.64M
수익:
$3.57M
순이익/손실:
$-15.74M
주가수익비율:
-0.1439
EPS:
-6.9481
순현금흐름:
$-15.77M
1주 성능:
-5.66%
1개월 성능:
-46.52%
6개월 성능:
-88.57%
1년 성능:
-95.86%
1일 변동 폭
$0.00
$0.00
1주일 범위
$1.00
$1.12
52주 변동 폭
$0.9601
$25.20
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.00 | 4.64M | 3.57M | -15.74M | -15.77M | -6.9481 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Icecure Medical Ltd 주식(ICCM)의 최신 뉴스
ICCMIcecure Medical Ltd | News - OTC Markets
A director will serve until November 2 as IceCure Medical (ICCM) removes his re-election agenda items. - Stock Titan
Part of IceCure Medical (ICCM)'s proposed chairman grant depends on at least $6.5 million in financing. - Stock Titan
ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally? - Stocktwits
Icecure Medical H1FY26 Results: Revenue up 45% YoY to $1.8 million - scanx.trade
IceCure Secures China NMPA Approval for ProSense Cryoablation System - Yahoo Finance
ICCM Looks 89.8% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
Icecure Medical Receives Regulatory Approval to Market Prosense in China - marketscreener.com
IceCure Medical (ICCM) secures China nod for tumor-freezing cancer tool - Stock Titan
China approves a tumor-freezing system from IceCure - Stock Titan
IceCure Medical Ltd. (ICCM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Icecure Medical Earnings Call Signals Early Growth Phase - TipRanks
IceCure and Scovas agree for ProSense distribution in Netherlands - Yahoo Finance
IceCure (ICCM) Results at a Glance: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings: Shares Move 6.58% Down in Latest TradingTax Rate Impact - vinanet.vn
Icecure Medical Ltd. Signs Exclusive Distribution Agreement with Scovas Medical for Prosense Cryoablation Systems in the Netherlands - marketscreener.com
IceCure (ICCM) Results at a Glance: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings: Shares Move 6.58% Down in Latest TradingTangible Book Value - careplusvn.com
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands - PR Newswire
IceCure (ICCM) Results at a Glance: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings: Shares Move 6.58% Down in Latest TradingEarnings Seasonality - dars.gov.et
IceCure (ICCM) Results at a Glance: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings: Shares Move 6.58% Down in Latest TradingEarnings Season Outlook - dars.gov.et
IceCure (ICCM) Earnings Report: Profit Per Share Falls Below Its Benchmark for the Current Session; Market Response - vinanet.vn
IceCure (ICCM) Earnings Report: Profit Per Share Falls Below Its Benchmark for the Current Session; Market Response - careplusvn.com
IceCure (ICCM) Earnings Report: Profit Per Share Falls Below Its Benchmark for the Current Session; Market Response: The Share Price Sheds 0.82% in the Latest ReadingSubscription Growth Report - www.dars.gov.et
IceCure Medical (ICCM): Commercial Adoption Is Improving, but the Reimbursement and Scale Story Still Needs More Proof - AlphaStreet
ICCM Looks 87.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
IceCure says West Cancer Center IRB clears ChoICE breast cancer cryoablation study - Bitget
IceCure's ProSense Is First and Only for Low-Risk Breast Cancer With FDA Marketing Authorization - Stock Titan
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation - PR Newswire
Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: R - GuruFocus
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript - AOL.ca
IceCure (ICCM) Earnings Report: EPS Misses Its Estimate under the Current Snapshot; Share Response - vinanet.vn
IceCure Medical Ltd. SEC Filing (Aug 19, 2026) - Stock Titan
IceCure (ICCM) Earnings Report: EPS Misses Its Estimate under the Current Snapshot; Share Response - careplusvn.com
IceCure (ICCM) Earnings Report: EPS Misses Its Estimate under the Current Snapshot; Share Response - www.dars.gov.et
IceCure (ICCM) Earnings Report: EPS Misses Its Estimate under the Current Snapshot; Share Response - dars.gov.et
IceCure Medical (ICCM) grants 131K RSUs to North America VP - Stock Titan
IceCure Medical : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
IceCure Medical (NASDAQ: ICCM) director lists no shares - Stock Titan
IceCure (NASDAQ: ICCM) VP now holds 106K shares and RSUs - Stock Titan
IceCure Medical (ICCM) awards COO 141K new RSUs - Stock Titan
IceCure Medical (NASDAQ: ICCM) adds 73,890 RSUs to VP HR stake - Stock Titan
IceCure Medical (ICCM) director Chan Vincent leaves board - Stock Titan
ICCM Looks 85.8% Undervalued on GF Value™ - GuruFocus
IceCure Medical (NASDAQ: ICCM) awards CFO 181K stock units at $0 - Stock Titan
IceCure Medical director David Salton files initial beneficial ownership statement - Bitget
IceCure Medical (ICCM) expands 2024 employee share incentive reserve - Stock Titan
Armistice Capital (ICCM) reports 300,332 IceCure Medical shares under shared control - Stock Titan
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
IceCure Medical (ICCM) Earnings Call zum 2. Quartal 2026: Umsatz im 1. Halbjahr steigt um 45 % - TradingKey
IceCure Medical (ICCM) details 324,802-share warrant issuance and $9.7M potential proceeds - Stock Titan
New studies highlight FDA-approved ProSense cry... - pluang.com
Icecure Medical Ltd (ICCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.73%
1.62%
자본화:
|
볼륨(24시간):